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DOI 10.1016/j.ccr.2011.06.010SUMMARYThe histone 3 lysine 79 (H3K79) methyltransferase Dot1l has been implicated in the development of leuke-
mias bearing translocations of theMixed Lineage Leukemia (MLL) gene. We identified theMLL-fusion targets
in an MLL-AF9 leukemia model, and conducted epigenetic profiling for H3K79me2, H3K4me3, H3K27me3,
and H3K36me3 in hematopoietic progenitor and leukemia stem cells (LSCs). We found abnormal profiles
only for H3K79me2 on MLL-AF9 fusion target loci in LSCs. Inactivation of Dot1l led to downregulation of
direct MLL-AF9 targets and an MLL translocation-associated gene expression signature, whereas global
gene expression remained largely unaffected. Suppression of MLL translocation-associated gene expres-
sion corresponded with dependence of MLL-AF9 leukemia on Dot1l in vivo. These data point to DOT1L
as a potential therapeutic target in MLL-rearranged leukemia.INTRODUCTION
Chromatin-modifying enzymes are central components of the
epigenetic machinery that control developmental programs. It
has become increasingly clear that these enzymes are also
critical for cancer development (Albert and Helin, 2010; Chi
et al., 2010). Genes encoding histone methyltransferase EZH2
and DNA methyltransferase DNMT3a are frequently mutated
in hematopoietic malignancies (Ernst et al., 2010; Ley et al.,
2010; Morin et al., 2010; Nikoloski et al., 2010), and recent trials
have demonstrated clinical efficacy of epigenetic-directed
therapies with histone deacetylase and DNA methyltransferase
inhibitors (Griffiths and Gore, 2008; Issa, 2007). However, it
remains unclear how to predict which patients will respond toSignificance
MLL-rearranged leukemias carry a poor prognosis, and eluc
by MLL-fusion proteins may facilitate the development of targ
that specifically involves H3K79 methylation on MLL-fusion ta
of MLL fusion-driven transcriptional programs. The aberrant
of H3K79 methylation for the maintenance of the MLL trans
MLL-rearranged leukemias are driven by an aberrant epigen
because Dot1l is one of few enzymes linked to MLL-fusion pro
target.
66 Cancer Cell 20, 66–78, July 12, 2011 ª2011 Elsevier Inc.epigenetic-directed therapies because clearly defined abnor-
malities in epigenetic pathways are often lacking. Identification
of defined cancers that depend upon specific epigenetic abnor-
malities should lead tomore informed use of therapies that target
epigenetic programs.
Prominent examples of a cancer driven by mutations involving
an epigenetic regulator are leukemias bearing translocations
involving the Mixed Lineage Leukemia (MLL) gene. Wild-type
MLL possesses a methyltransferase domain, which modifies
histone H3 on lysine 4 (Milne et al., 2002; Nakamura et al.,
2002), that is absent in the oncogenic fusion protein (Ayton
and Cleary, 2001; Krivtsov and Armstrong, 2007). Biochemical
studies have shown that several common MLL-fusion oncopro-
teins copurify with protein complexes normally associatedidating the biological processes underlying transformation
eted therapies. Here, we demonstrate an epigenetic lesion
rget genes. Loss of Dot1l selectively decreases expression
H3K79 methylation pattern and the specific requirement
location-associated oncogenic program demonstrate that
etic program. This has profound therapeutic implications
teins and, as such, may represent an important therapeutic
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H3K79 Methylation in MLL-Rearranged Leukemiawith transcriptional elongation (Mohan et al., 2010b). At least
three complexes, PAFc, DOT1L, and pTEFb (also designated
AEP or SEC), bind MLL-fusion proteins. The polymerase-
associated factor complex (PAFc) regulates RNA polymerase II
and associates with the NH3-terminal portion of wild-type
MLL and MLL-fusion proteins (Muntean et al., 2010). The pTEFb
complex (CDK9/cyclinT), which phosphorylates RNA poly-
merase II, interacts with MLL-fusion partners such as ENL,
ELL (as well as ELL2, ELL3), AF4, and AF5 (Lin et al., 2010; Yo-
koyama et al., 2010) and copurifies with several MLL-fusion
proteins. The DOT1L complex consists of DOT1L, a histone
methyltransferase that modifies Histone H3 on lysine 79
(H3K79), and multiple MLL-fusion partners such as AF9, ENL,
and AF10 (Bitoun et al., 2007; Mohan et al., 2010a; Mueller
et al., 2007, 2009; Okada et al., 2005; Zhang et al., 2006). Based
on these biochemical data, it appears that MLL fusions directly
stimulate transcriptional elongation via recruitment of
complexes that lead to deregulated transcription. However,
how these complexes interact with each other and the extent
to which each contributes to MLL fusion-mediated leukemia
development remain unclear.
The interaction between MLL-fusion proteins and DOT1L has
prompted assessment of H3K79 methylation in MLL-fusion
leukemia models and patient samples. Enhanced H3K79 meth-
ylation has been associated with genes overexpressed in MLL
fusion-driven leukemias (Guenther et al., 2008; Krivtsov and
Armstrong, 2007; Krivtsov et al., 2008). In particular, enhanced
H3K79 methylation has been described on several known
MLL-fusion target loci including the 50 HoxA cluster genes
(HoxA7-13) and Meis1 (Guenther et al., 2008; Krivtsov et al.,
2008; Milne et al., 2005). Several groups have demonstrated
that Dot1l is required for transformation of murine bone marrow
cells with MLL-AF10 (Okada et al., 2005), MLL-AF9, (Chang
et al., 2010; Jo et al., 2011; Nguyen et al., 2011), and possibly
MLL-AFX (Chang et al., 2010; Okada et al., 2005).
Because histone H3K79 dimethylation (H3K79me2) is
a histone mark associated with actively transcribed genes, it
has been hypothesized that DOT1L may play an active role in
maintenance of MLL fusion-mediated gene expression (Krivt-
sov and Armstrong, 2007; Okada et al., 2005). Genome-wide
analysis of MLL-rearranged leukemia samples has revealed
unique transcriptional and H3K79 methylation profiles that
can distinguish MLL-rearranged leukemias from MLL-germline
leukemias (Armstrong et al., 2002; Ross et al., 2004; Krivtsov
et al., 2008). Thus, it is possible that the institution of abnormal
histone methylation patterns at key loci is a crucial step in MLL
fusion-mediated transformation. However, the near-ubiquitous
association of H3K79 methylation with transcription is an argu-
ment against a specific role for Dot1l in MLL fusion-mediated
leukemogenesis (Steger et al., 2008). In addition, to our knowl-
edge, whether a single chromatin mark can specifically regulate
a leukemogenic transcription program is unknown. In this study
we determine genome-wide histone methylation profiles for
multiple modifications in normal hematopoietic progenitor
cells and MLL-AF9 driven leukemia stem cells (LSCs), define
the MLL-AF9 target genes with an associated aberrant
H3K79me2 profile, and assess the dependence of MLL
fusion-mediated gene expression and leukemia maintenance
on DOT1L.RESULTS
MLL-AF9 Target Loci Are Associated with H3K79me2
in Abnormal Amount and Distribution
Previous reports (Guenther et al., 2008) demonstrated the
presence of aberrant levels of H3K79me2 and perhaps
H3K4me3 atMLL-AF4 target genes in a human cell line harboring
an MLL-AF4 translocation. We assessed for the presence of
a similar epigenetic lesion in a mouse model of MLL-AF9 LSCs
defined previously as Il-7RLinSca-1c-Kit+CD34+FcgRII/III+
leukemic granulocyte-macrophage progenitors (L-GMPs)
(Krivtsov et al., 2006). We identified the genome-wide localiza-
tion of H3K79me2 in L-GMPs by chromatin immunoprecipitation
(ChIP) followed by next-generation sequencing (ChIP-Seq). In
additionwe identified directMLL-AF9 fusion protein target genes
through use of metabolic labeling of MLL-AF9 with biotin fol-
lowed by ChIP-Seq using streptavidin. Significant H3K79me2
was found associated with 5507 genes (Figure 1A; see Table
S1 available online). MLL-AF9 was bound to the promoter region
of 139 genes (Table S1), 120 of which also had significant
H3K79me2 (Figure 1A) (p = 1.2e–14). The target genes include
genes with known functional significance in MLL-rearranged
leukemia biology such as HoxA cluster genes and Meis1, and
less well-defined targets such as Runx2 and Jmjd1c (Figure S1).
GeneSet Enrichment Analysis (GSEA) showed that expression of
the 139MLL-AF9 targets is highly enriched in L-GMPs compared
to the corresponding normal granulocyte-macrophage progeni-
tors (GMPs) (p% 0.001), suggesting that transduction with MLL-
AF9 causes increased expression of its direct targets (Figure 1B).
We analyzed the relationship between the amount of H3K79me2
and gene expression, and found a strong positive correlation
(Figure 1C). Globally, H3K79me2 levels peaked sharply just
downstream of the transcription start site (TSS), and the height
of the peak correlated with the amount of mRNA transcribed
from the respective locus (Figure 1C). We analyzed the
H3K79me2 profile of MLL-AF9 target genes in L-GMPs and
observed a consistent perturbation of this pattern, with a higher
peak, and wider spatial distribution of the H3K79me2 modifica-
tion to both sides of the TSS (Figures 1D and 1E). To further
assess the association of H3K79me2 with MLL-AF9 targets,
we created a control set of another 139 genes that showed
increased expression in L-GMPs compared to GMPs but were
not direct MLL-AF9 targets. The level of H3K79me2 in the control
set is the same as expected for highly expressed genes (Fig-
ure 1D). Therefore, an H3K79me2 epigenetic lesion is present
at MLL-AF9 target loci in murine MLL-AF9 L-GMPs.
In order to test the relevance of this finding in human leuke-
mias, we performed ChIP-Seq for H3K79me2 on a primary
MLL-AF9 rearranged AML sample obtained at diagnosis. We
created groups of genes with defined expression levels utilizing
a published gene expression data set ofMLL-rearranged human
primary patient samples (Ross et al., 2004), and again found
a strong correlation between global expression levels and the
presence of H3K79me2 (Figure 1F, red and blue lines). Next,
we analyzed H3K79me2 profiles at loci corresponding to the
MLL-AF9 targets defined in the mouse model. We observed an
increase in H3K79me2 peak signal height and distribution
comparable to the murine H3K79me2 profiles (Figure 1F). For
further characterization we overlapped our murine MLL-AF9Cancer Cell 20, 66–78, July 12, 2011 ª2011 Elsevier Inc. 67
Figure 1. Presence of an H3K79me2 Epigenetic Lesion on Direct MLL-AF9 Fusion Targets
(A) ChIP-Seq for H3K79me2 and MLL-AF9 in MLL-AF9 transformed cells. The whole genome view denotes regions associated with H3K79me2 (5507 genes,
light-green tracks; p = 0.02) and MLL-AF9-Bio (MLL-AF9 direct targets, 139 genes, dark-green tracks; p = 0.0005). Venn Diagram demonstrating overlap of
MLL-AF9 direct targets and genes associated with H3K79me2.
(B) GSEA of the 139 MLL-AF9 direct target genes demonstrating enrichment of gene expression for MLL-AF9 targets in LSCs (L-GMP) versus normal murine
GMPs (p < 0.001).
(C) H3K79me2ChIP-Seq signal height and position are shown relative to TSS for genes grouped according to their expression level inMLL-AF9 L-GMPs (No, dark
blue; High, red).
(D) Height and distribution of H3K79me2 profiles around the TSS of MLL-AF9 targets (brown) compared to nontargets with similar expression levels (green).
(E) H3K79me2 profiles of selected MLL-AF9 targets and nontargets.
(F) H3K79me2 signal height and position similar to (D) in human MLL-rearranged AML. H3K79me2 ChIP-Seq was performed on a human MLL-AF9 rearranged
primary AML sample. The 139 MLL-AF9 target loci determined in (A) converted to 120 MLL-AF9 target loci in the human genome, defining the MLL-AF9
direct targets (brown). Control gene sets with differential expression levels were created from a previously published expression array data set on human
MLL-rearranged AML (Ross et al., 2004) (green).
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H3K79 Methylation in MLL-Rearranged Leukemiatarget gene set with a recently published list of MLL-AF4 targets
(Guenther et al., 2008), thus establishing a core set of common
MLL-fusion targets (Table S1). When interrogating human
leukemia H3K79me2 profiles at the core MLL-fusion target
loci, the presence of an epigenetic lesion became even more
pronounced (Figure 1G). By comparison, H3K79me2 patterns
on MLL-AF9 targets in an AML control patient sample with
a normal karyotype were normal and mirrored that of the nontar-
get control gene set and other highly expressed genes (Figures
1H and 1I). These findings demonstrate an H3K79me2 epige-
netic lesion at MLL-fusion target genes specifically in human
primary leukemia cells bearing an MLL translocation.
MLL-AF9 Disrupts the Relationship between H3K79me2
and Other Histone Modifications
Previous studies have demonstrated a molecular connection
between H3K4me3 and H3K79 methylation (Lee et al., 2007).
Thus, we asked whether the abnormal H3K79me2 methylation
patterns correlated with additional epigenetic abnormalities on
MLL-AF9 target loci. There may be a concomitant increase of
H3K79me2 with other transcription-associated marks such as
H3K4me3 and H3K36me3, which could reflect increased tran-
scriptional activity at these loci. Alternatively, H3K79me2 hyper-
methylation could override a presumptive need for H3K4me3
and/or H3K36me3 for transcription initiation or elongation,
resulting in lower association of MLL-fusion target loci with
these modifications. We assessed H3K79me2, H3K4me3, and
H3K36me3, which are associated with active gene expression,
and H3K27me3, which is associated with repression of gene
expression, in MLL-AF9 L-GMPs, as well as normal hematopoi-
etic stem cell-enriched LSK cells (Lin, Sca-1+, c-Kit+), and
GMPs (Figure 2A). In addition we correlated histone modification
profiles with previously published gene expression profiles for
these same populations (Krivtsov et al., 2006). This afforded us
an integrated view of epigenetic and gene expression changes
as cells undergo transitions from LSK to GMP, and from GMP
to L-GMP. Figure 2A shows the histone methylation patterns
on the HoxA cluster for all assessed populations, and the region
targeted by MLL-AF9. The 50 HoxA cluster genes are expressed
in LSK cells, and associated with H3K4me3, H3K36me3,
and H3K79me2. As cells differentiate to GMPs, H3K4me3,
H3K36me3, and H3K79me2 decrease as does gene expression.
Furthermore, adjacent H3K27me3 spreads into the 50 HoxA
cluster. In L-GMPs the H3K27me3, H3K4me3, and H3K36me3
patterns are reversed to profiles comparable with LSK cells. In
contrast, H3K79me2 showed an increased amount and
abnormal pattern as defined above.
On a genome-wide scale, there were no major differences in
the number of loci associated with H3K4me3, H3K27me3,
H3K36me3, or H3K79me2 in LSK, GMP, and L-GMPpopulations
(LSK: 4142 genes are associated with H3K79me2; GMP: 5002,
L-GMP 5507). However, when looking at locus-specific combi-(G) H3K79me2 profiles relative to the TSS for a list of ‘‘core’’ targets (turquoise) de
gene set of MLL-AF4 direct targets identified in a human MLL-AF4 rearranged c
(H) H3K79me2 profiles relative to the TSS of MLL-fusion target genes expr
rearrangement).
(I) H3K79me2 profiles relative to the TSS for ‘‘core targets’’ (defined as in G), in a
See also Figure S1 and Table S1.nations, differences emerged (Figures 2B and 2C; Figure S2A–
S2L). In LSK and GMP, there is a positive correlation between
H3K4me3 and H3K79me2 (Figure 2B; Figure S2A), and
H3K36me3andH3K79me2 (FiguresS2DandS2E). Thepresence
of H3K27me3 and H3K79me2 was mutually exclusive (Figures
S2G and S2H). There was also an inverse correlation between
H3K27me3 and H3K36me3 (Figures S2J and S2K). In LSK and
GMP the relationship between H3K4me3 and H3K79me2 is
preserved for MLL-fusion target loci (shown in red, Figure 2B
and Figure S2A). In contrast, MLL-fusion target loci in L-GMPs
acquire an abnormal histone methylation pattern characterized
by increased H3K79me2, resulting in a disturbed ratio of
H3K4me3 and H3K79me2 (Figure 2C). A similar pattern emerges
for H3K79me2 and H3K36me3 (Figure S2F). The normal levels of
H3K4me3 and H3K36me3 on MLL-AF9 target loci suggest that
abnormal H3K79me2 does not substitute for H3K4me3 or
H3K36me3. We also analyzed the distribution of H3K4me3,
H3K27me3, and H3K36me3 with respect to the TSS in LSK,
GMP, and L-GMP populations (Figure S2M). In contrast to
H3K79me2 (Figure 1D), there were no differences in H3K4me3,
H3K27me3, and H3K36me3 profiles between MLL-fusion target
genes and nontarget genes in L-GMPs, or between MLL-fusion
target genes in L-GMP versus LSK or GMP populations.
Next, we assessed changes in H3K79me2 with respect to
changes in gene expression either during normal development
(LSK versus GMP), or during leukemia development (L-GMP
versus GMP). As cells differentiate from LSK to GMP, changes
in expression mirror changes in H3K79me2, and this correlation
is maintained for MLL-AF9 targets (Figure 2D). Conversely, when
comparing changes in expression and H3K79me2 in L-GMP
versus GMP cells, MLL-AF9 targets stand out as acquiring
H3K79me2 in excess of what would be expected based on
changes in expression alone (Figure 2E). This is restricted to
MLL-AF9 target genes in MLL-AF9 leukemias: nontarget genes
that are upregulated in L-GMP versus GMP, and MLL-AF9
target loci that are physiologically regulated during the LSK
to GMP transition maintain normal H3K79me2 patterns. The
H3K79me2-specific epigenetic lesion suggests that the expres-
sion of MLL-fusion target genes may depend on H3K79me2 to
a far greater extent in MLL-rearranged cells than in other (normal
or malignant) cells, and that inhibition of H3K79 methylation
might specifically downregulate MLL fusion-driven transcrip-
tional programs.
Loss of Dot1l Leads to Differentiation, Cell Cycle
Changes, and Apoptosis in MLL Fusion-Driven
Leukemia Cells
To establish that Dot1l and H3K79 methylation are indeed
required for the maintenance of MLL fusion-driven transcrip-
tional programs and leukemogenesis, we developed a condi-
tional knockout mouse model for Dot1l. In this model, exon 5
of Dot1l, which encodes most of the methyltransferase activefined as the overlap of the direct MLL-AF9 targets with a previously published
ell line.
essed in a control AML patient sample with a normal karyotype (no MLL
control AML patient sample with a normal karyotype.
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Figure 2. Relationship between H3K79me2 and Other Histone Modifications on Direct MLL-AF9 Fusion Targets
(A) ChIP-Seq for H3K4me3, H3K27me3, H3K36me3, and H3K79me2 in sorted LSK, GMP, and L-GMP populations. A screen shot of the HoxA cluster
shows changes in these epigenetic marks during normal development (LSK and GMP), and in MLL-AF9 driven leukemogenesis (L-GMP). Also shown are
MLL-AF9 fusion ChIP-Seq in MLL-AF9 transformed cells (MLL-AF9-Bio) and differential gene expression in L-GMP versus GMP as assessed by expression
array (Expr L-GMP versus GMP); color legend denotes fold change.
(B) Genome-wide representation of the relation between H3K4me3 and H3K79me2 in LSK cells on fusion target genes (red) compared to nonfusion target
genes (gray).
(C) Genome-wide representation of the relation between H3K4me3 and H3K79me2 in L-GMP on fusion target genes (red) compared to nonfusion target
genes (gray).
(D) Changes in expression between LSK and GMP (obtained by expression array, x axis) in correlation to changes in H3K79me2 (ChIP-Seq, y axis). This
correlation is shown for MLL-AF9 targets in red, and nontargets in gray.
(E) Changes in expression between L-GMP andGMP in correlation with changes in H3K79me2. Shown is the amount of H3K79me2 signal difference for MLL-AF9
target genes (red) compared to genes that show similar differences in expression between L-GMP and GMP but are not MLL-fusion targets (gray).
See also Figure S2.
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H3K79 Methylation in MLL-Rearranged Leukemiasite (Min et al., 2003), is flanked by two loxP sites (Figures S3A–
S3C). Homozygous Dot1lf/f mice are phenotypically normal and
display normal blood counts (Figures S3D–S3F). We trans-
formed lineage-depleted (lin) Dot1lf/f and Dot1l+/f bone70 Cancer Cell 20, 66–78, July 12, 2011 ª2011 Elsevier Inc.marrow cells with retrovirus expressing MLL-AF9 (Krivtsov
et al., 2006). Transformed cells were subsequently transduced
with retroviruses encoding either Cre-recombinase and YFP
(MSCV-Cre-IRES-YFP, ‘‘Cre’’) or YFP (MSCV-IRES-YFP,
Figure 3. Loss of Dot1l Leads to Decreased Growth, Differentiation, and Apoptosis of MLL-AF9 Murine Leukemia Cells
(A) Immunoblot analysis for H3K79me2 in MLL-AF9 transformed cells of the indicated genotype 4 days after transduction with Cre or control retrovirus.
(B) Blast colony count of Dot1l-deleted MLL-AF9 transformed cells (/) in methylcellulose 10 days after transduction with Cre in comparison to controls (n =
at least 3 independent experiments).
(C) H3K79me2 ChIP-qPCR from in vivo-established MLL-AF9 leukemia cells on days 3, 5, and 7 after transduction with Cre. Loss of H3K79me2 is statistically
significant on days 5 and 7 for HoxA7, HoxA9, HoxA11, Meis1, and Actin at p < 0.05 (n = 2–3 independent experiments for each time point).
(D) Morphologic changes (colony morphology in methylcellulose, Wright-Giemsa stain) and H3K79me2 immunofluorescence (Alexa 594-H3K79me2 and DAPI
nuclear stain) in established MLL-AF9 leukemia cells 10 days after transduction with Cre.
(E) Cell cycle changes (BrdU/7-AAD flow cytometry) inMLL-AF9 leukemia cells 7 days after transductionwith Cre (n = 3 independent experiments). *G0/1 increase
significant at p < 0.02 (+/f), p < 0.04 (+/), and p < 0.02 (f/f); decrease in S-phase significant at < 0.0002 (+/f), p < 0.0009 (+/) and p < 0.0003 (f/f).
(F) Induction of apoptosis (annexin+/PI) in MLL-AF9 leukemia cells 10 days after transduction with Cre (n = 3 independent experiments).
Error bars represent standard error of the mean (SEM). See also Figure S3.
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H3K79 Methylation in MLL-Rearranged Leukemia‘‘MIY’’) and sorted for GFP/YFP double-positive cells. Introduc-
tion of Cre into transformed cells led to a near-complete loss of
H3K79me2 in Dot1l/ cells (Figure 3A). Complete deletion of
Dot1l profoundly decreased the number of blast-like colonies
in methylcellulose that could be recovered after 1 week (Fig-
ure 3B). In addition, Dot1l/ colonies were smaller compared
to control colonies (data not shown).
Next, we analyzed fully developed MLL-AF9 leukemias.
Primary recipient mice were transplanted with MLL-AF9-GFP
transformed lin cells from either Dot1l+/f or Dot1lf/fmice. Estab-
lished leukemias were isolated from moribund mice and trans-
duced with Cre or control vector. Loss of H3K79me2 on several
MLL-AF9 target genes (50 HoxA cluster genes and Meis1) was
assessed by ChIP followed by quantitative PCR (qPCR).
H3K79me2 at these loci was completely absent 5 days after
retroviral transduction (Figure 3C). As observed for the in vitro-
transformed cells, colony formation of Dot1l/ MLL-AF9
leukemia cells was greatly reduced, and colonies were smaller
and less compact (Figure 3D). Control colonies were comprised
of abundant cells with blast-like morphology, whereas loss of
Dot1l induced profound morphologic changes consistent with
terminal differentiation (Figure 3D). Loss of Dot1l also reduced
the number of actively proliferating cells, with themajority of cells
shifted toward G0/G1 (Figure 3E). In addition to morphologicand cell cycle changes, we observed a modest increase in the
percentage of apoptotic cells after deletion of Dot1l (Figure 3F).
We conducted additional studies in human MLL-rearranged
leukemia cells using an shRNA approach, which yielded overall
similar results with MLL-rearranged cells being more consis-
tently affected by DOT1L suppression than MLL-germline cells
(Figures S3G–S3M).
Loss of Dot1l Has Little Effect on Myeloid Progenitors
and HoxA9/Meis1a-Transformed Cells
In order to determine if loss of Dot1l might nonspecifically inhibit
proliferation of all hematopoietic cells, we inactivated Dot1l in
normal bone marrow and analyzed deleted cells in myeloid
progenitor assays (Figure 4A). Dot1l+/+, Dot1l+/f, and Dot1lf/f
bonemarrow transduced with Cre showed amoderate decrease
in plating efficiency and colony size when compared to MIY-
transduced control populations. However, there was no signifi-
cant difference between the three Cre-transduced populations
(Figures 4A; Figure S4A and S4B). Thus, in this short-term assay
we observed clear differential sensitivity between MLL-AF9
transformed cells (Figure 3B), and normal myeloid progenitors
(Figure 4A).
Given the limited replating potential of committed myeloid
progenitors, we conducted additional experiments using aCancer Cell 20, 66–78, July 12, 2011 ª2011 Elsevier Inc. 71
Figure 4. Colony Formation of Normal Hematopoietic Progenitors and HoxA9/Meis1a-Transformed Cells Is Unaffected by Loss of Dot1l
(A) Colony formation of normal hematopoietic progenitors 10 days after Cre-mediated excision of exon 5 of Dot1l (Dot1lf/f Cre) compared to controls
(3–5 independent experiments).
(B) Blast colony count of HoxA9/Meis1a-transformed cells inmethylcellulose after transduction with Cre in comparison to controls over 3 weeks of serial replating
(3–5 independent experiments).
(C) Serial assessment of H3K79me2 in HoxA9/Meis1a blast colonies over 3 week replating.
(D) Blast colony size and morphology in methylcellulose of Dot1l-deleted and Dot1l wild-type HoxA9/Meis1a-transformed cells.
(E) Homing (18 hr) and engraftment (11 days) of Dot1lf/f and Dot1l/ cells after injection of 5 3 105 HoxA9/Meis1a-transformed cells (3 days after transduction
with Cre or MIY). In vivo BrdU labeling demonstrates actively dividing cells. All differences are not statistically significant.
Error bars represent SEM. *p < 0.05. ns, not significant. See also Figure S4.
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H3K79 Methylation in MLL-Rearranged Leukemiamyeloid leukemia model where leukemic transformation is
driven by introduction of HoxA9 and Meis1a (Wang et al.,
2010) into LSK cells. In contrast to MLL-AF9 cells, complete
deletion of H3K79me2 in HoxA9/Meis1a-transformed cells had
no impact on the number of blast-like colonies in methylcellulose
during serial replating (Figure 4B). Tracking of H3K79me2 re-
vealed outgrowth of a small proportion of cells that had escaped
full deletion in later passages (Figure 4C). Morphologically,
HoxA9/Meis1a-transformed Dot1l/ colonies were indistin-
guishable from control colonies (Figure 4D). When transplanted
into mice, Dot1l/ cells were able to efficiently home to the
bone marrow (Figure 4E). Eleven days after transplantation,
both populations had dramatically expanded (100-fold). BrdU
incorporation revealed actively dividing cells in similar propor-
tions in both groups. Western blot analysis of sorted cells from
these animals revealed reemergence of H3K79me2, albeit at
a low level (Figure S4C). This suggests that whereas Dot1l/
HoxA9/Meis1a-driven leukemia cells are at a slight disadvantage
to Dot1l heterozygous or wild-type cells, they are still able to
proliferate and expand substantially.72 Cancer Cell 20, 66–78, July 12, 2011 ª2011 Elsevier Inc.Loss of Dot1l Specifically Decreases Expression
of MLL-AF9 Targets
We next examined gene expression changes in MLL-AF9
leukemia cells after loss of Dot1l. H3K79 methylation has
previously been reported to be ubiquitously coupled to
transcription (Steger et al., 2008), raising the question whether
loss of Dot1l would lead to widespread collapse of transcription.
On the other hand, the aberrant amount and pattern of
H3K79me2 could indicate that MLL-fusion targets would be
more sensitive to Dot1l loss. Leukemic bone marrow from mice
transplanted with Dot1lf/f MLL-AF9 cells was transduced with
retroviral Cre or control vector. RNA was purified 3, 5, and
7 days after transduction, amplified, and hybridized to murine
Affymetrix 430 2.0 microarrays. We identified the genes differen-
tially expressed at day 5 for further analysis because the major
gene expression changes appeared firmly established by this
time point (Figure S5). We found that despite the large number
of loci associated with H3K79me2 (>5000, Figure 1A), only
a small subset of genes showed a change in expression at
p < 0.01 (Figure 5A). In addition we observed comparable
Figure 5. Loss of Dot1l Specifically Decreases Expression of MLL Fusion-Driven Transcriptional Programs
(A) Expression array of MLL-AF9 mouse leukemia cells 5 days after loss of Dot1l. Shown are all probe sets/genes with differential expression at p = 0.01, as well
as a list of the top 25 differentially expressed genes.
(B) Change in relative expression of actin after loss of H3K79me2 associated with the actin promoter (Figure 3C).
(C) Example for overlay of ChIP-Seq results for H3K79me2 (light green) and MLL-AF9 direct targets (dark green) with expression array results for genes that
are differentially downregulated (blue, Dot1l-down signature) after loss of Dot1l (shown: chromosome 17).
(D) GSEA showing enrichment of MLL-AF9 direct targets in ‘‘Dot1l-down’’ signature (p = 0.01).
(E) GSEA showing enrichment of ‘‘Dot1l-down’’ signature in LSCs (L-GMP) versus normal progenitors (GMP) (p < 0.01).
(F) GSEA showing enrichment of ‘‘Dot1l-down’’ signature in human MLL-rearranged versus non- MLL-rearranged primary patient samples (p = 0.034).
See also Figure S5 and Table S2.
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Dot1l-up signature) and decreased (92 probe sets [70 genes],
Dot1l-down signature) expression (p < 0.01) (Figure 5A; Table
S2). This indicates that expression of the majority of genes asso-
ciated with H3K79me2 did not significantly change after loss of
this modification. As an example, the actin promoter is associ-
ated with H3K79me2, and although the methyl mark is lost after
deletion of Dot1l (Figure 3C), actin expression remains largely
unchanged (Figure 5B). In contrast, analysis of the set of genes
with significantly decreased expression (Dot1l-down signature)
revealed many genes known to be important in MLL-mediatedleukemogenesis such as HoxA7-11 (Armstrong et al., 2002;
Kawagoe et al., 1999; Zeisig et al., 2004), Mef2C (Krivtsov
et al., 2006), and Meis1a (Zeisig et al., 2004) (Figure 5A), as
well as newly identified MLL-AF9 direct targets such as Arid2
or Runx2 (Figure 5C). To investigate whether MLL-AF9 targets
are enriched in the Dot1l-down set of genes, we performed
GSEA and found significant enrichment of the MLL-AF9 targets
in the Dot1l-down signature (p = 0.01) (Figure 5D). We next
used GSEA to assess enrichment of the Dot1l-down signature
in several previously published gene expression data sets.
Dot1l-down was highly enriched in a gene set distinguishingCancer Cell 20, 66–78, July 12, 2011 ª2011 Elsevier Inc. 73
Figure 6. Hematopoietic Development in the Absence of Dot1l
(A) Peripheral blood counts ofDot1lf/f Vav-Cre (black squares, n = 8) compared to littermate controls (open squares, n = 12) at 3–6weeks of age. Squares and error
bars represent first and second standard deviation. Normal range is shaded green. Inset shows immunoblot for H3K79me2 in peripheral blood nucleated cells
of Dot1lf/f Vav-Cre and control mice.
(B) Colony formation of normal hematopoietic progenitors from bone marrow of Dot1lf/f Vav-Cre mice. Colonies were scored 7–8 days after plating. Dot1lf/f
Vav-Cre, n = 5; Dot1l+/f, n = 5; Dot1l+/f Vav-Cre, n = 3 (3 independent experiments). Error bars, SEM. All differences were not statistically significant exceptDot1lf/f
Vav-Cre versus Dot1l+/f Vav-Cre in CFU-GM.
(C) Bone marrow cellularity in Dot1lf/fVav-Cre mice shown as total cells recovered from front and hind legs plus pelvis. Dot1lf/f Vav-Cre (/) (n = 9), Dot1lf/f (f/f)
(n = 4), Dot1l+/f Vav-Cre (+/) (n = 3), and Dot1l+/f (+/f) (n = 10) mice. Error bars, SEM.
(D) Flow cytometric analysis of hematopoietic stem and progenitor cell compartments in Dot1lf/fVav-Cre mice. Dot1lf/f Vav-Cre (n = 4), Dot1lf/f (n = 3), Dot1l+/f
Vav-Cre (n = 4), and Dot1l+/f (n = 3) mice from 3 separate litters. ns, not significant. Error bars represent SEM.
See also Figure S6.
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counterpart (GMP) (p < 0.001) (Figure 5E). To assess the rele-
vance of our signature to human disease, we performed GSEA
on a data set from human MLL and non-MLL rearranged AML
(Ross et al., 2004). The Dot1l-down list was significantly enriched
in the human MLL-rearranged AML samples (p = 0.034) (Fig-
ure 5F). These results demonstrate that global expression
patterns remain largely unaffected upon loss of Dot1l, whereas
a small subset of genes whose expression is decreased are
highly enriched for direct MLL-AF9 targets.
Loss of Dot1l Results in Impaired, but Not Absent,
Hematopoiesis
In order to investigate whether Dot1l is required for nonmalignant
hematopoietic development, we crossed Dot1lf/f mice with Vav-
Cremice (Georgiades et al., 2002) to delete Dot1l throughout the
hematopoietic compartment starting during embryonal develop-
ment (Figure 6). Dot1lf/f Vav-Cre mice were born in expected
frequencies with essentially normal body and organ weights
(Figures S6A–S6C). Young mice (3–6 weeks) displayed varying
degrees of anemia (Figure 6A) and were mild to moderately
neutropenic and lymphopenic. The colony-forming activity of
myeloid progenitors appeared relatively intact (Figure 6B), with
a trend toward a more severe phenotype in earlier compart-74 Cancer Cell 20, 66–78, July 12, 2011 ª2011 Elsevier Inc.ments. The total bone marrow cellularity in these mice was
decreased (Figure 6C). However, loss of Dot1l did not lead to
complete loss of myeloid or lymphoid development. Dot1l/
peripheral blood leukocytes with confirmed absence of
H3K79me2 developed and expanded up to 3–6 weeks postna-
tally and were readily isolated from these mice (Figure 6A). The
LSK, GMP, and CMP (common myeloid progenitor; Il-
7RLinSca-1c-Kit+CD34+FcgRII/IIIlo) compartments were
moderately to severely decreased. Megakaryocyte/erythroid
progenitors (MEP, Il-7RLinSca-1c-Kit+CD34-FcgRII/III)
were less affected (Figure 6D). Analysis of older mice was chal-
lenging due to partial chimerism with nondeleted clones that
over time contributed to varying degrees to the hematopoietic
phenotype (data not shown). These results point to a role for
Dot1l during hematopoietic development but also demonstrate
that hematopoiesis can develop to some extent in the absence
of Dot1l.
MLL-AF9LeukemiaCells AreDependent onDot1l In Vivo
In order to assess the role of Dot1l in leukemia development
in vivo, lin Dot1lf/f and Dot1l+/f bone marrow cells were trans-
formed using retroviral MLL-AF9. Subsequently, Dot1l was
deleted in preleukemic-transformed cells through retroviral
delivery of Cre-recombinase. Two to 4 days after transduction,
Figure 7. Dot1l Is Required for Transformation and Maintenance of MLL-AF9 Fusion-Driven Leukemia In Vivo
(A) Survival curves for mice injected with 13 105 MLL-AF9 transformed lineage negative bone marrow cells 2–4 days after transduction with Cre or MIY-control
retrovirus and resorting for GFP+/YFP+ cells.
(B) Survival curves for secondary recipient mice that received 13 105 MLL-AF9 leukemia cells isolated from leukemic mice that were subsequently transduced
with Cre or MIY-control retrovirus 3 days prior to reinjection. Just prior to reinjection, cells were resorted for GFP+/YFP+ cells.
See also Figure S7.
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and injected into sublethally irradiated recipients. MLL-AF9
transformed Dot1lf/f and Dot1l+/f cells transduced with control
retrovirus, and Dot1l+/f cells transduced with Cre rapidly and reli-
ably caused clinically overt leukemia, with most animals having
succumbed by 150 days (Figure 7A). Transduced Dot1l+/ cells
exhibited a small but consistent increase in latency that reached
statistical significance. In contrast, MLL-AF9 transformed
Dot1l/ cells failed to cause leukemia in the majority of recipi-
ents. Leukemia that did develop in one recipient of MLL-AF9
transformed Dot1l/ cells was derived from cells that had failed
to undergo full rearrangement of Dot1l alleles, and contained
normal H3K79me2 levels (Figure S7C), a phenomenon we also
observed in vitro (Figures S7A and S7B). These results demon-
strate that Dot1l is necessary for MLL-AF9 mediated leukemia
development in vivo.
Next, we studied the consequence of loss of Dot1l in estab-
lished MLL-AF9 leukemia. Dot1lf/f or Dot1l+/f AML was isolated
from moribund mice and transduced with either Cre or control
vector. Sorted cells were injected into sublethally irradiated
secondary recipients 3 days after transduction. At this time point,
neither the epigenetic changes (complete loss of H3K79me2,
Figure 3C) nor the gene expression changes observed after
loss of Dot1l (Figure S5) were fully established, andDot1l/ cells
were indistinguishable from control cells with respect to growth
pattern or the percentage of transduced cells. Transplantation of
established MLL-AF9 AML into secondary recipients after dele-
tion of Dot1l failed to cause disease (Figure 7B). A small differ-
ence was again observed between mice that received Dot1l+/
leukemia cells and those that received Dot1l+/f leukemias, but
the difference did not reach statistical significance.
DISCUSSION
The results presented here demonstrate that MLL-AF9 myeloid
leukemia is driven by an aberrant epigenetic program involving
H3K79 methylation. A potential role for Dot1l inMLL-rearranged
leukemia is supported by multiple publications in recent years.
However, the contribution of Dot1l and H3K79 methylation with
respect to other hypotheses of MLL fusion-driven leukemogen-
esis, and the importance of H3K79me2 in the maintenance of
gene expression remained unclear. H3K79 methylation has
been reported to be near ubiquitously coupled to transcription(Steger et al., 2008), a fact that has raised serious concerns
about the specificity of the dependence of MLL-rearranged
leukemia cells on Dot1l. It was also unclear if a single and rela-
tively abundant histone modification could exert locus-specific
effects on a highly selective gene set that controls the MLL-
fusion associated leukemogenic transcription program.
We demonstrate an absolute dependence of MLL-AF9
leukemia cells on Dot1l in vitro and in vivo, and propose amolec-
ular rationale for this finding by identifying a distinct epigenetic
lesion specifically involving H3K79me2. We identified the direct
targets of the MLL-AF9 fusion protein in a murine MLL-AF9
leukemia model, allowing us to assess chromatin states specif-
ically at MLL-AF9 targets. We discovered highly abnormal
H3K79me2 patterns at MLL-AF9 target loci, which were unique
both with respect to other transcriptionally active loci within
the same cell, and with respect to the same loci when expressed
at the same level but under physiologic regulation in normal
hematopoietic progenitors. These abnormalities could explain
a specific and nonphysiological dependence of the MLL
fusion-driven leukemogenic transcription program on H3K79
methylation. Consistent with this hypothesis, only a small
subgroup of genes, which was highly enriched for MLL-fusion
targets and other genes with known functions inMLL-rearranged
leukemias, showed any change in expression after loss of Dot1l
and H3K79 methylation. This group of genes showed significant
overlap with gene expression signatures that define murine
MLL-AF9 LSCs and human MLL-rearranged clinical leukemia
samples. On the other hand, transcription of the majority of
genes associated with H3K79me2 did not depend on the
presence of this chromatin mark. Although our studies do not
address the role of H3K79 methylation with respect to initiation
or elongation, they do suggest that H3K79me2 is not uniformly
involved in maintaining transcription. Rather, the exquisite and
specific sensitivity of MLL-AF9 leukemia cells to loss of H3K79
methylation may be a consequence of the uniquely abnormal
H3K79 methylation patterns at key loci. It is of tremendous
interest to determine whether the dependence of MLL-fusion
associated expression programs constitutes an overreliance
on an inappropriately targeted, but otherwise normal, Dot1l, or
whether Dot1l is aberrantly regulated in these leukemias.
Our data support a role for Dot1l in normal hematopoiesis.
Conditional Dot1l knockout mice expressing Cre from a hemato-
poiesis-specific promoter exhibit a moderate reduction in whiteCancer Cell 20, 66–78, July 12, 2011 ª2011 Elsevier Inc. 75
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as well as earlier progenitor compartments. This phenotype is
similar to the hematopoietic phenotype recently reported in
a conditional Dot1l CreER model (Jo et al., 2011). Analysis of
embryonic blood development in Dot1l mutant mice revealed
a severe defect in early erythroid, but not myeloid, development
(Feng et al., 2010). Earlier studies support a role for Dot1l in the
transcriptional regulation of the a- and b-globin loci (Fu et al.,
2005; Sawado et al., 2008). Taken together, these studies
provide evidence for a critical role of Dot1l in early hematopoietic
and particularly erythroid development; therefore, anemia or
pancytopenia may be potential side effects of pharmacologic
inhibition of Dot1l. However, complete deletion of c-kit results
in severe anemia, bone marrow failure, and embryonic lethality,
whereas clinically effective pharmacologic inhibition of c-kit
with imatinib is verywell toleratedwith onlymodest andmanage-
able hematopoietic side effects (Broxmeyer et al., 1991). The fact
that the isolation of near-uniformly Dot1l/ peripheral blood
leukocytes from 3- to 6-week-old mice is possible demonstrates
that Dot1l is not absolutely required for all hematopoietic cells,
and suggests an exploitable therapeutic window.
To our knowledge, Dot1l is the only known methyltransferase
for H3K79 and is responsible for monomethylation, dimethyla-
tion, and trimethylation of this residue. Monomethylation, dime-
thylation, and trimethylation may fulfill divergent biological roles.
Genome occupancy of H3K79me2 and H3K79me3-modified
histones in yeast is mutually exclusive, and associated with
distinct biological processes (Schulze et al., 2009). Our study
assessed only the genome-wide methylation patterns for
H3K79me2 due to lack of specific antibodies that recognize
H3K79me3. Our study does not address whether loss of
monomethylation, dimethylation, or trimethylation is the most
detrimental to MLL-rearranged leukemia cells. This question is
not trivial because the addition of methyl groups by Dot1l
appears to be sequential, and the conversion of H3K79me2 to
H3K79me3 requires prior ubiquitination of histone H2B, hinting
at amuchmore complex epigenetic network potentially involving
additional histone modifications.
In summary our findings demonstrate a strong rationale and
imply a therapeutic window for pharmacologic inhibition of
Dot1l as a strategy to targetMLL-rearranged leukemias. Further
studies will determine the exact molecular mechanisms of how
abnormal H3K79 methylation patterns are established and how
mistargeting of a single epigenetic modification may act as
a master regulator of transcriptional programs that lead to
leukemic transformation.
EXPERIMENTAL PROCEDURES
For primer and shRNA sequences, antibodies, and detailed experimental
procedures, please refer to the Supplemental Experimental Procedures.
Human Samples
The samples from patients with AML were provided by the German-Austrian
AML Study Group (AMLSG) with patient-informed consent for genetic analysis
according to the Declaration of Helsinki, and institutional review board
approval from all participating centers. Conventional chromosome banding
and fluorescence in situ hybridization (FISH) were performed as previously
described (Schlenk et al., 2008). The samples included in the study contained
at least 80% of leukemic cells following Ficoll-density gradient centrifugation-
based enrichment.76 Cancer Cell 20, 66–78, July 12, 2011 ª2011 Elsevier Inc.Generation of a Dot1l Knockout Mouse and Breeding
Animals weremaintained at the Animal Research Facility at Children’s Hospital
Boston. Animal experiments were approved by the Internal Animal Care and
Use Committee. A pFlexibleª-based targeting vector containing exon 5 of
Dot1l flanked by loxP sites was used to target CJ9 ES cells (129 background).
Conditional mice were maintained on a B6/129 (Taconic) background or
crossed to Vav-Cre (kindly provided by Dr. Stuart Orkin).
Generation of Transformed Murine Cells and Leukemia
Ecotropic retroviral vectors containing murine MLL-AF9 IRES-GFP, HoxA9-
IRES-GFP, Meis1a-pgk-Puro, Cre, and MIY were generated by cotransfection
of 293 cells. lin or LinSca-1+c-Kit+ cells were transduced with MLL-AF9-
GFP or HoxA9 IRES-GFP andMEIS1a-pgk-Puro and maintained in methylcel-
lulose with supplemental cytokines. After 2–6 days, GFP+ cells were sorted
and transduced with Cre or MIY. Two to 4 days after transduction, GFP+/
YFP+ cells were sorted and transplanted into B6/129 syngeneic sublethally
irradiated (600 rad) recipients at 13 105 or 53 105 cells/mouse. For secondary
transplants, whole-bone marrow from leukemic mice was isolated, GFP+ cells
were sorted, and blast colonies were allowed to grow out. Leukemic cells were
transduced with Cre or MIY, sorted, and transplanted as described above.
Biochemical Assays (Cell Growth, Apoptosis, Cell Cycle Analysis,
Western Blotting, qPCR)
Cell growth and viability were followed by serial cell counts. Apoptosis and
cell cycle analysis were performed using the Annexin-staining and BrdU-
APC/7AAD kit from BD PharMingen (San Jose, CA, USA). Antibodies used
for immunoblot detection on whole-cell lysates or histones are detailed in
Supplemental Experimental Procedures. For colony assays, sorted trans-
duced leukemia cells were plated in methylcellulose M3234 containing IL3,
IL6, and SCF at 1000 or 5000 cells per plate, and replated weekly at 1000 cells
per plate. Normal, nontransformed bonemarrowwas plated inmethylcellulose
M3434 at 20000 cells per plate, and colonies were scored on days 8–9.
ChIP-qPCR and ChIP-Seq
Hematopoietic progenitor populations (LSK and GMP) and LSCs (L-GMP)
were isolated by flow cytometry. For ChIP of MLL-AF9, 5-FU-treated bone
marrow was in vitro transformed with C-terminal HA-biotagged MLL-AF9.
Results using MLL-AF9-HAbio L-GMPs isolated from the bone marrow of
transplanted mice yielded similar results, and for brevity are not included in
this study. ChIP was performed as previously described (Bracken et al.,
2006; Krivtsov et al., 2008). Briefly, crosslinking was performed with 1%
formalin, and the cells were lysed in SDS buffer. DNA was fragmented by
sonication. ChIP for H3K4me3, H3K27me3, H3K36me3, and H3K79me2 was
performed using antibodies specific to the respective modifications. ChIP
for MLL-AF9 was performed using streptavidin for precipitation of biotinylated
MLL-AF9. Eluted DNA fragments were analyzed by qPCR, or subjected to
sequencing using next-generation Solexa sequencing.
RNA Amplification and Gene Expression Array
RNA was isolated from 105-sorted GFP+/YFP+ cells using TRIzol (Invitrogen),
amplified (Ovation Pico WTA; NuGEN, San Carlos, CA, USA), labeled (NuGEN
Encore Biotin Module), and hybridized to Affymetrix 430 2.A murine
microarrays.
Data Analysis and Statistical Methods
Precipitated DNA from ChIP experiments was sequenced on Illumina
Genome Analyzer IIx or HiSeq 2000 platform. Sequence reads were aligned
to mouse genome assembly mm8 or human genome assembly hg18 using
Bowtie (Langmead et al., 2009). Reads that aligned to multiple loci in the
genome were discarded. The ChIP-Seq signal was quantified as total number
of reads per million in the region 1 kb upstream of TSS to 2 kb downstream
of TSS for H3K79me2 and 1 kb upstream of TSS to 1 kb downstream of
TSS for MLL-AF9. An empirical background distribution model of reads
was constructed to find the significance level of signal at a gene. Expression
array data were analyzed with GenePattern (Reich et al., 2006) release
3.2.3 (http://www.broad.mit.edu/tools/software.html), and the probe sets
were mapped to genes using library files (version 30) downloaded from the
Affymetrix website (http://www.affymetrix.com). GSEA was performed using
Cancer Cell
H3K79 Methylation in MLL-Rearranged Leukemiawww.broadinstitute.org/gsea. The integrative analysis of histone modification
levels and gene expression was performed using iCanPlot (htt://www.
icanplot.org) (A.U.S., unpublished data).
ACCESSION NUMBERS
Microarray andChIP-Seq data have been deposited at the NCBI Gene Expres-
sion Omnibus (http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/geo/)
with accession codes GSE25911 (Expression changes after loss of Dot1l
in murine MLLAF9 leukemia cells) and GSE29130 (Epigenetic profiling of
hematopoietic stem cells and leukemia stem cells).
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